Gemcitabine in locally advanced and/or metastatic bladder cancer
- 31 May 2000
- journal article
- review article
- Published by Elsevier in Critical Reviews in Oncology/Hematology
- Vol. 34 (3) , 175-183
- https://doi.org/10.1016/s1040-8428(00)00060-3
Abstract
No abstract availableKeywords
This publication has 24 references indexed in Scilit:
- Weekly gemcitabine and cisplatin combination therapy in patients with transitional cell carcinoma of the urothelium: A phase II clinical trialAnnals of Oncology, 1999
- Long-Term Survival in Metastatic Transitional-Cell Carcinoma and Prognostic Factors Predicting Outcome of TherapyJournal of Clinical Oncology, 1999
- Gemcitabine Plus Cisplatin, an Active Regimen in Advanced Urothelial Cancer: A Phase II Trial of the National Cancer Institute of Canada Clinical Trials GroupJournal of Clinical Oncology, 1999
- Outcome of Postchemotherapy Surgery After Treatment With Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Patients With Unresectable or Metastatic Transitional Cell CarcinomaJournal of Clinical Oncology, 1999
- Global cancer statisticsCA: A Cancer Journal for Clinicians, 1999
- A phase II study of gemcitabine in patients with transitional cell carcinoma of the urinary tract previously treated with platinumEuropean Journal Of Cancer, 1998
- Chemotherapy for urothelial tract malignancies: Breaking the deadlockSeminars in Surgical Oncology, 1992
- M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for advanced carcinoma of the bladderEuropean Journal of Cancer and Clinical Oncology, 1991
- Cancer in the European community and its member statesEuropean Journal of Cancer and Clinical Oncology, 1990
- Long-term follow-up in patients treated with methotrexate, vinblastine, doxorubicin, and cisplatin (M-VAC) for transitional cell carcinoma of urinary bladder: Cause for concernUrology, 1989